There is an increasing interest in the underlying mechanisms of the antidepressant and anxiolytic treatment effect associated with changes in serotonergic neurotransmission after treatment with selective serotonin (5-HT) reuptake inhibitors (SSRIs) in humans. The 5-HT 1A receptor is known to play a crucial role in the pathophysiology of affective disorders, and altered 5-HT 1A receptor binding has been found in anxiety patients. SSRI treatment raises the 5-HT level in the synaptic cleft and might change postsynaptic receptor densities. Therefore, our study in patients suffering from anxiety disorders investigated the effects of long-term treatment with escitalopram on the 5-HT 1A receptor. A longitudinal positrone emission tomography (PET) study in 12 patients suffering from anxiety disorders was conducted. Two dynamic PET scans were performed applying the selective 5-HT 1A receptor antagonist [carbonyl-11 C]WAY-100635. Eight regions of interest were defined a priori (orbitofrontal cortex, amygdala, hippocampus, subgenual cortex, anterior and posterior cingulate cortex, dorsal raphe nucleus and cerebellum as reference). After the baseline PET scan, patients were administered escitalopram (average dose of 11.2 ± 6.0 mg day À1 ) for a minimum of 12 weeks. A second PET scan was conducted after 109±27 days. 5-HT 1A receptor binding potentials in 12 patients were assessed by PET applying the Simplified Reference Tissue Model.There was a significant reduction in the 5-HT 1A receptor binding potential after a minimum of 12 weeks of escitalopram treatment in the hippocampus (P = 0.006), subgenual cortex (P = 0.017) and posterior cingulate cortex (P = 0.034). The significance of the hippocampus region survived the Bonferroni-adjusted threshold for multiple comparisons. These PET data in humans in vivo demonstrate a reduction of the 5-HT 1A binding potential after SSRI treatment.
Introduction
Preclinical and clinical investigations have provided comprehensive evidence of impaired serotonin (5-HT) neurotransmission in affective disorders such as depression and anxiety disorders. Different subtypes of 5-HT receptors are suggested to play a key role in this altered neurotransmission. Gross and co-workers 1,2 reported a strong involvement of the 5-HT 1A receptor in the development of anxious behaviour in animal models of anxiety. In recent studies, reduced 5-HT 1A receptor binding was found in patients suffering from depression, [3] [4] [5] panic disorder (PD) 6 and social anxiety disorder. 7 There is growing interest in the role of both presynaptic autoreceptors and postsynaptic receptors in the therapeutic action of selective serotonin reuptake inhibitors (SSRIs).
5,8-11
The presynaptic 5-HT 1A autoreceptors are located on serotonergic neurons in the dorsal raphe nuclei, thus inhibiting cell firing and 5-HT synthesis, consequently reducing 5-HT release. 12 Postsynaptic 5-HT 1A receptors are found in limbic and cortical brain regions and mediate the inhibitory serotonergic influence on GABAergic and glutaminergic neurons. [13] [14] [15] Several preclinical studies in rodents have shown that the SSRI-induced increase in extracellular 5-HT is associated with a desensitization of 5-HT 1A somatodendritic autoreceptors, thus providing a biological rationale for the delayed antidepressive and anxiolytic effects of SSRI treatment. [16] [17] [18] [19] This desensitization of 5-HT 1A autoreceptors occurring during treatment with SSRIs attenuates the autoinhibitory effect of these receptors on 5-HT release and thus enhances serotonergic neurotransmission. 12, 20, 21 Chronic SSRI treatment has been shown to result in postsynaptic 5-HT 1A receptor desensitization 22, 23 in some brain regions. This desensitization was found in the amygdala 11 and in the orbitofrontal cortex. 24 In 1991, Pandey et al. 25 showed a significant decrease in 5-HT 1A receptor binding in cortical regions of rat brains after antidepressant treatment with desipramine and electroconvulsive therapy. Following this, Beck et al. 26 described an alteration in the 5-HT 1A receptor-mediated hyperpolarization of hippocampal cells after fluoxetine application whereas only CA1 but not CA3 layer cells showed this alteration. Furthermore, Nishi and Azmitia 27 reported a decrease in 5-HT 1A receptor mRNA expression and 5-HT 1A receptor protein levels in fetal hippocampal cell cultures when treated with an agonist (8-OH-DPAT). In contrast, Klimek et al. 28 revealed an increase in the 5-HT 1A receptor density after a 2-week citalopram administration in male wistar rats. In the living human brain, David et al. 29 demonstrated lower 5-HT 1A receptor binding in subjects with 5-HTTLPR short (SS or SL) genotypes associated with reduced 5-HT transporter and increased synaptic 5-HT levels than in subjects with long (LL) genotypes.
In accordance with these findings, Patel et al.
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depicted an adaptive increase of 5-HT 1A expression following reduced 5-HT innervation, thus suggesting a high potential in adaptive changes in 5-HT 1A receptor expression. However, relatively little is known about the plasticity of these receptors in the human brain. The present study aims to assess the influence of long-term treatment with escitalopram on 5-HT 1A receptor binding potential in patients suffering from anxiety disorders. Escitalopram, the S-enantiomer of citalopram, 31, 32 is a potent antidepressant 33, 34 and anxiolytic agent. 35, 36 Given the huge interpatient variability and gender differences in 5-HT 1A receptor binding, 37, 38 we performed a longitudinal study in a group of 16 male patients with social phobia or PD. Regarding the 5-HT 1A receptor binding potential, we expected a lowering in several brain regions mainly caused by chronically increased 5-HT levels in the interstitial compartment after 12 weeks of escitalopram treatment compared to the pretreatment level. 21 
Materials and methods
This study was approved by the Ethics Committee of the Medical University of Vienna and the General Hospital of Vienna.
Patients
We enrolled 16 medication-free male outpatients aged 23-56 years (31.3 ± 8.6 mean age ± s.d.) suffering from social anxiety disorder or PD in the study. Patients were recruited either by advertisements or from the outpatient clinic. All patients underwent a medical examination including general physical and neurological status, electrocardiogram and routine laboratory screening. All included patients were physically healthy and right handed. Two earlier studies reported a reduced 5-HT 1A receptor binding potential (non-displaceable binding potential (BP ND )-consensus position on nomenclature for binding potential has recently been published by Innis et al. 39 ) in patients suffering from depression. 3, 40 Therefore, patients with depression or comorbid axis I diagnoses were not included in the study. This also applied to patients with a history of alcohol or drug abuse. Regarding treatment effects, 9,41,42 on the 5-HT 1A BP ND , only patients who were naive to psychotropic drug treatment targeting the serotonergic system were enrolled.
According to the Diagnostic and Statistical Manual of Mental Disorders-IV criteria, social anxiety disorder or PD was diagnosed by means of psychiatric consultation, the Mini International Neuropsychiatric Interview 43 and the Spielberger State Trait Anxiety Inventory (STAI) 44 on the day of the screening visit carried out by two experienced psychiatrists. The STAI was also performed prior to the two positrone emission tomography (PET) measurements. Five of 16 patients also fulfilled the criteria for agoraphobia.
Each patient was enrolled after fulfilling the inclusion criteria and providing written informed consent at the screening visit. All patients participating in the study received reimbursement.
Four patients were excluded from the statistical analysis resulting in a study population of nine patients with social phobia and three patients with PD. Two of the excluded participants were not compliant regarding medication intake, one showed alcohol abuse during the participation (several positive alcohol blood tests at study visits). Following Rabiner et al.
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, we had to exclude one more patient from further analysis. The area under the curve of the reference region time activity curve (TAC) of this patient was outside the two standard deviation limits previously determined. 45 Table 1 summarizes the demographic characteristics and treatment variables of the patients included. 
PET measurements
Scanning procedures were performed as previously described 7 and will be summarized briefly. All patients were PET scanned using a GE Advance PET scanner (General Electric Medical Systems, Milwaukee, WI, USA) at the Department of Nuclear Medicine of the Medical University of Vienna, Austria. To cover the cerebellum in the field of view, the head of each patient was placed in the scanner parallel to the orbitomeatal line by means of a laser beam system. A cushion made of polyurethane and straps around the forehead and chin of the patient were used to minimize head movements. For the correction of tissue attenuation, a 5-min transmission scan was carried out by a retractable 68 Ge ring source. Dynamic PET scans started simultaneously with intravenous bolus injection of [carbonyl- Regions of interest and tracer kinetic modelling A PET summation image for each single patient was generated as an intensity summation of dynamic PET images of all 30 time points by means of the volume addition tool of PMOD 2.7. 47 The individual MR image of each participant was co-registered to the PET summation image 48 applying the software package Statistical Parametric Mapping, version 2002 (SPM2). 49 The selection of the regions of interest (ROIs) was in accordance with those ROIs previously defined 7 based on the functional magnetic resonance imaging and PET literature in anxiety disorders 6, [50] [51] [52] [53] [54] [55] with the addition of two limbic structures, that is, subgenual cortex (subgenual region of the anterior cingulate cortex) and posterior cingulate cortex, for a total of eight regions: anterior cingulate cortex, posterior cingulate cortex, orbitofrontal cortex, amygdala, hippocampus, subgenual cortex, dorsal raphe region and the cerebellum. All were drawn bilaterally on coregistered MR images in accordance with the anatomical criteria of Bremner et al., 56 except for the orbitofrontal cortex, subgenual cortex and the dorsal raphe region (for example see Figure 1 ). The subgenual cortex region was defined as the lower part of the anterior cingulate cortex below the rostral boundary of the corpus callosum. Given the lack of MR criteria for raphe boundaries, the ROI of the raphe region in the midbrain had to be directly delineated on the PET summation image. Owing to the partial volume effect resulting from the small dimensions (volume of 71.3 ± 4.5 mm 3 ) of the human dorsal raphe nucleus, 57 an exact delineation of this region is hampered. Hence, we identified the slices showing the interpeduncular cistern on the co-registered MR image. On the corresponding slices of the PET summation image, we delineated a cubic ROI with a pre-assigned volume of 747 mm 3 at the dorsal midbrain area containing high tissue signal. 55 The volume of 747 mm 3 was chosen to provide a basis of comparison to other investigations of the 5-HT 1A receptor distribution commonly assuming ROI sizes of this area ranging from 600 55 to about 2000 mm 3 .
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As the true dimensions of the dorsal raphe nuclei are much smaller than these volumes, 57 the true magnitude of the 5-HT 1A BP ND must necessarily be underestimated due to spillover of radioactivity.
The estimation of 5-HT 1A receptor distribution in this study was performed with the kinetic modelling tool of PMOD 2.7 (PMOD Technologies Ltd, Zurich, Switzerland), 47 applying Lammertsma's Simplified Reference Tissue Model. 58 This model is based on a two-tissue compartment approach, using the cerebellum as reference region because of its small number of 5-HT 1A receptors. 14, 59 Decay-corrected TACs for each ROI were generated for the calculation of the regional 5-HT 1A BP ND s applying PMOD 2.7 and the Simplified Reference Tissue Model, whereas the latter shows high sensitivity to differences in the radioligand kinetics of the reference region. Therefore, we analysed the TACs of the reference region (cerebellum) and found no significant difference between the areas under the curve of these TACs when comparing the PET measurements before and after treatment with the SSRI (T = À1.34 P > 0.05). As mentioned before, one patient was excluded from further analysis because of the area under the curve of his reference region TAC falling outside two standard deviations of the mean.
Statistical analysis
All statistical analyses were performed by means of SPSS 12.0.1 (SPSS Inc., Chicago, IL, USA). To scrutinize the normal distribution and equality of variance, the Kolmogorov-Smirnov test ( > 0.05) and the Levene's test ( > 0.05) have been performed. The level of significance was set at Pp0.05, and all parametric tests were applied two-tailed. Significance levels were corrected for multiple comparisons (seven ROIs) using a Bonferroni adjusted value of Pp0.0071.
To examine treatment effects of 12 weeks of escitalopram intake, paired sample t-tests were performed comparing regional 5-HT 1A RPB values at the first and the second PET scan. Furthermore, paired sample t-tests of anxiety state scores (STAI) at the screening visit and the two PET scans were undertaken. To exclude effects of radiochemical variables on the regional BP ND s, a multiple regression analysis including the regional BP ND s (dependent variables), the applied dosage and plasma levels of escitalopram, age and the radiochemical variables (independent variables) was performed.
To exclude any impact of demographic or radiochemical variables on the 5-HT 1A binding potential, Pearson product moment correlation coefficients were obtained for age, applied escitalopram dosage and plasma levels, STAI state scores as well as total injected dose, specific activity, weight of WAY-100634 and weight of unlabelled WAY-100635 against the regional BP ND s of the two PET measurements.
Results

5-HT 1A receptor binding potential before and after escitalopram treatment in limbic ROIs
There was a significant reduction of the 5-HT 1A BP ND in the hippocampus after 12 weeks of SSRI treatment (T = 3.352, P = 0.006). Furthermore, a statistically significant decrease of the 5-HT 1A BP ND in the subgenual cortex (T = 2.797, P = 0.017) and the posterior cingulate cortex (T = 2.420, P = 0.034) was observed (see Figure 2 ). Regions such as the orbitofrontal cortex (T = 2.048, P = 0.065) and anterior cingulate cortex (T = 2.034, P = 0.067) were borderline significant. The significance value of the hippocampus region survived the Bonferroni correction for multiple comparisons (Pp0.0071). Details of the per cent reduction (%) of 5-HT 1A BP ND are given in Table 2 .
There were nonsignificant trends towards decreased BP ND in the dorsal raphe nuclei (T = 1.395, P = 0.190) and the amygdala (T = 1.503, P = 0.161) (see Table 2 ).
A multiple regression analysis excluded a significant effect of age and radiochemical variables on the difference in 5-HT 1A BP ND between PET1 and PET2.
STAI state anxiety scores and 5-HT 1A receptor binding potential All patients reported an improvement in clinical symptoms after 12 weeks of escitalopram treatment. Likewise, there was a significant decrease in the STAI state anxiety scores when comparing the values at the screening visit (P = 0.009) and PET1 (P = 0.014) with PET2 (see Figure 3) . There was also a slight but not statistically significant reduction between the STATE scores at the screening visit and PET1 (P > 0.05).
Pearson product moment correlation coefficients between the STAI state anxiety scores and the postsynaptic 5-HT 1A BP ND s reached statistically significant levels in hippocampus (r = 0.50, P = 0.012), amygdala (r = 0.42, P = 0.043), subgenual cortex (r = 0.51, P = 0.010), anterior cingulate cortex (r = 0.53, P = 0.007) and orbitofrontal cortex (r = 0.56, P = 0.004) when PET results and psychological test scores from both scanning sessions were pooled (see Figure 4) . The correlation coefficient between the Spielberger STATE scores and the presynaptic 5-HT 1A BP ND s in the dorsal raphe nuclei was also significant (r = 0.51, P = 0.011). Only the correlations between STAI scores and the reductions in the anterior cingulate and the orbitofrontal cortices still remain Escitalopram and serotonin-1A receptor C Spindelegger et al significant after Bonferroni correction for multiple comparisons.
5-HT 1A receptor binding potential, demographic and radiochemical variables
There were no significant correlations of the regional 5-HT 1A BP ND s with age or injected dose, specific activity, weight of WAY-100634 and weight of unlabelled WAY-100635 at the two PET measurements before and after escitalopram treatment (results not shown).
Discussion
The main finding of this PET study is a significant reduction of 5-HT 1A BP ND in the hippocampus, the subgenual cortex and the posterior cingulate cortex after long-term treatment with escitalopram Escitalopram and serotonin-1A receptor C Spindelegger et al in patients suffering from anxiety disorders. Sargent et al. 5 reported a modest but not statistically significant reduction of 5-HT 1A BP ND only in the raphe nuclei in 10 patients suffering from depression after 6 weeks of treatment with paroxetine, whereas five of these patients were non-responders to the treatment. Furthermore, Bhagwagar et al. 9 suggested a persistent reduction of 5-HT 1A BP ND in clinically recovered Lesch et al. 8 reported in two neuroendocrine studies a reduction in the responsiveness of 5-HT 1A receptors in patients suffering from anxiety disorders or depression, as well as obsessive-compulsive disorders after chronic treatment with fluoxetine 60 more than a decade ago, suggesting an alteration of these receptors. Furthermore, a reduction in the 5-HT 1A receptor-mediated inhibition of adenylyl cyclase activity has been reported in rat brain after chronic SSRI treatment with fluoxetine, 61 although this was not a consistent finding. 62 Subsequently, 5-HT 1A receptor-mediated feedback of the amygdala regulating the serotonergic firing rate in the dorsal raphe nuclei was proven to diminish after long-term SSRI treatment. 11 Together, these results indicate a high plasticity and reactivity of these receptors during chronic antidepressant treatment.
The binding potential is defined as receptor density divided by the distribution constant K d (B max /K d ) relative to the V d (distribution volume of the ligand in a non-binding region) of the tracer. Therefore, treatment-induced reduction of 5-HT 1A BP ND with a single PET examination at high specific activity of the radioligand might be based on a reduced number of available receptors, reduced affinity of the radioligand to the receptor by either increased K d or increased competition between the endogenous 5-HT and the applied radioligand, or both. The findings of our study do not allow us to exactly distinguish between the possibilities of a potential competition of the 5-HT level with the applied tracer, a reduction in the receptor affinity or a decrease in the receptor density.
The decreased 5-HT 1A BP ND could be based on an increase of 5-HT levels in the synaptic cleft induced by SSRI treatment initiating a competition between tracer and 5-HT at these receptors. Hume et al. 28 who reported no significant change in the K d of 5-HT 1A receptors after acute or 2-week administration of citalopram, it seems to be unlikely that the reduced BP ND is evoked by lowering the tracer apparent affinity in the presence of an endogenous competitor. This does not exclude the possibility of SSRI-induced changes of affinity for the receptor by transcriptional or post-transcriptional effects on the 5-HT 1A BP ND .
Another explanatory approach suggests a decreased availability of regional 5-HT 1A receptors in limbic regions after SSRI treatment. This could be explained by a lower receptor affinity or a decreased number of available receptors. Meyer et al. 66 reported a downregulation of the major excitatory 5-HT 2A receptors after a 6 week-period of paroxetine treatment. This suggestion was based on the assumption that the receptor binding potential reflects receptor density divided by the distribution constant K d (B max /K d ). This enables the attribution that downregulation could either be mediated through a decreased receptor density or through a decreased receptor affinity (resulting in an increased dissociation constant), whereas ex vivo studies only reported receptor changes after long-term agonist administration mediated through a reduction of the receptor density. 67 However, Klimek et al. 28 reported an increased 5-HT 1A receptor density after 2 weeks of citalopram administration, with K d remaining constant suggesting a high plasticity of these receptors. Consistent with these findings, we can not exclude that decreased 5-HT 1A BP ND s revealed in our study are caused by a reduction in receptor density.
Anxiety scores and 5-HT 1A receptors
Our results suggest a significant reduction of the STAI state anxiety scores after 12 weeks of escitalopram treatment. We also did not find a statistically significant reduction in the STAI state anxiety scores between the screening visit and the first PET scan. This decrease can be explained by a treatment effect of the ambulant therapeutic setting after the inclusion of the patients into the study. Furthermore, we found a significant positive correlation between the STAI state anxiety scores and the 5-HT 1A BP ND in several limbic regions when combining the anxiety scores of both PET measurements, even if the correlations between state anxiety and the 5-HT 1A receptor binding potential did not reach statistical significance when analysing only PET1 and PET2. We suggest that there is lack of power due to the large intersubject variability regarding the 5-HT 1A receptor binding potential.
The significant findings support the assumption of the crucial involvement of 5-HT 1A receptors in the pathophysiology of anxiety disorders as reported by various authors. 2, 6, 7 On the basis of the present findings, we can exclude the possibility that differences in radiochemical variables or changes in the area under the curve of the reference region between first and second PET scan explain the reduced 5-HT 1A receptor binding following treatment by multiple regression analysis. In addition, we have earlier performed an unpublished test-retest study in healthy subjects at our PET centre. The size of the mean error between scan 1 and scan 2 ranged from 0.2 to 16.3% in the tested ROIs (data not shown). These findings are in good agreement with published studies. 37, 68 Therefore, the mean reduction of 28.2% in 5-HT 1A receptor binding in the hippocampus is in excess of the variability of the test-retest quantification.
Conclusion
To our knowledge, this is the first PET study reporting a significant decrease in 5-HT 1A receptor binding after long-term SSRI treatment of patients suffering from anxiety disorders. The results suggest that long-term escitalopram administration might cause a decrease in the inhibitory modulation of 5-HT on GABAergic and glutaminergic neurons mediated by a reduction of 5-HT 1A receptors in limbic regions.
